Sanofi wins European approval for rare blood-clotting disorder treatment

FILE PHOTO: The logo of Sanofi is pictured during the Viva Tech start-up and technology summit in Paris, France, May 25, 2018. REUTERS/Charles Platiau/File Photo

PARIS (Reuters) – French drugmaker Sanofi on Monday said it had secured approval in Europe for a rare blood-clotting disorder treatment using nanobodies. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in June had recommended the approval of caplacizumab, which is to be prescribed to adults suffering acquired thrombotic thrombocytopenic purpura […]

Continue reading this article with a Fiji Times online membership.

More Stories